Use of Hormone Replacement Therapy in the Asymptomatic Postmenopausal Woman: What is the Current Evidence?

Annals of the Academy of Medicine Singapore

Volumn 32, Issue 5, 2003, Pages 605-610

  Loh, Foo Hoe ^a  

^a Women's Hlth Professionals Pte L   (Singapore)

Author keywords

Hormone replacement therapy; Menopausal symptoms; Women's Health Initiative

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGE; AGED; AGING; ALZHEIMER DISEASE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; EARLY MENOPAUSE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FRACTURE; HEALTH; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; METHODOLOGY; PHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGAPORE; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VASOMOTOR DISORDER;

EID: 0242551109     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, et al, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal Results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
2. Hu F B, Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. Am J Cardiol 2002; 90:26F-29F.
3. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson S R, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997; 27:261-74.
4. Grodstein F, Stampfer M J, Manson J E, Colditz G A, Willett W C, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-61.
5. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047-59.
6. Chlebowski R T, Hendrix S L, Langer R D, Stefanick M L, Gass M, Lane D, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243-53.
7. Blake J M, Collins J A, Reid R L, Fedorkow D M, Lalonde A B, Christilaw J, et al. The SOGC (Society of Obstetricians and Gynaecologists of Canada) statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynaecol Can 2002; 24:783-90, 793-802.
8. American College of Obstetricians and Gynaecologists, August 2002. Questions and Answers on Hormone Therapy, In Response to the Women's Health Initiative Study Results on Estrogen and Progestin Hormone Therapy. (Accessed 4 July 2003, at http://www.acog.org/from_home/publications/press_releases/nr08-30-02.cfm)
9. Health Sciences Authority, Singapore. Expert Panel discourages use of hormone replacement therapy for prevention of coronary heart disease. (Accessed 3 October 2002, at http://app.internet.gov.sg/data/hsa/ PRelease- ExpertPanelDiscouragesUseofCombinedHRT%20forPreventionOfCoronaryHeartDisease- 3Oct02.pdf).
10. Loh F H, Khin L W, Saw S M, Gu K, Jeanette Lee J M. Singapore experience of a nation-wide study on the health issue among women undergoing the menopause transition-preliminary report. Am J Epidemiol 2001; 153:S142.
11. Barnabei V M, Grady D, Stovall D W, Cauley J A, Lin F, Stuenkel C A, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002; 100:1209-18.
12. Greendale G A, Reboussin B A, Hogan P, Barnabei V M, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998; 92:982-8.
13. Shulman L P, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002; 9:195-207.
14. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4:58-74.
15. St Germain A, Peterson C T, Robinson J G, Alekel D L. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001; 8:17-26.
16. Baber R J, Templeman C, Morton T, Kelly G E, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999; 2:85-92.
17. Knight D C, Howes J B, Eden J A. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2:79-84.
18. Loh F H, Chen L H, Yu S L, Jorgensen L N. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas 2002; 41:123-31.
19. Hays J, Ockene J K, Brunner R L, Kotchen J M, Manson J E, Patterson R E, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839-54.
20. Wiklund I, Karlberg J, Mattsson L A, Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 68:824-30.
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-13.
22. Ettinger B, Black D M, Mitlak B H, Knickerbocker R K, Nickelsen T, Genant H K, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-45.
23. Black D M, Cummings S R, Karpf D B, Cauley J A, Thompson D E, Nevitt M C, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
24. Brinton R D, Chen S, Montoya M, Hsieh D, Minaya J. The estrogen replacement therapy of the Women's Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease. Maturitas 2000; 34(Suppl 2):S35-52.
25. Zandi P P, Carlson M C, Plassman B L, Welsh-Bohmer K A, Mayer L S, Steffens D C, et al. Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288:2123-9.
26. Rapp S R, Espeland M A, Shumaker S A, Henderson V W, Brunner R L, Manson J E, et al, WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2663-72.
27. Shumaker S A, Legault C, Thal L, Wallace R B, Ockene J K, Hendrix S L, et al, WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651-62.
28. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al, WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673-84.
29. Hadjidakis D J, Kokkinakis E P, Sfakianakis M E, Raptis S A. Bone density patterns after normal and premature menopause. Maturitas 2003; 44:279-86.
30. Kalantaridou S N, Davis S R, Nelson L M. Premature ovarian failure. Endocrinol Metab Clin North Am 1998; 27:989-1006.
31. Everson S A, Matthews K A, Guzick D S, Wing R R, Kuller L H. Effects of surgical menopause on psychological characteristics and lipid levels: the Healthy Women Study. Health Psychol 1995; 14:435-43.